Thrombosis Research
Volume 118, Issue 3 , Pages 385-395 , 2006

Thromboembolism and anticoagulant management in hemodialysis patients: A practical guide to clinical management

  • Dorothy S. Lo

      Affiliations

    • Department of Medicine, McMaster University, Hamilton, ON, Canada
    • ,
  • Christian G. Rabbat

      Affiliations

    • Department of Medicine, McMaster University, Hamilton, ON, Canada
    • ,
  • Catherine M. Clase

      Affiliations

    • Department of Medicine, McMaster University, Hamilton, ON, Canada
    • Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada
    • Corresponding Author InformationCorresponding author. 25 Charlton Ave. East, Suite 708, Hamilton, ON, Canada, L8N 1Y2. Tel.: +1 905 521 6094; fax: +1 905 521 6153.

Received 4 March 2005 ,Revised 4 March 2005 ,Accepted 8 March 2005.

References 

  1. United States Renal Data System . USRDS 2002 annual data report: atlas of end-stage renal disease in the United States. http://www.usrds.org/adr.htm2002;National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD
  2. Canadian Organ Replacement Register . Annual report 2000. Dialysis and renal transplantation. vol. 1. Ottawa: Canadian Institute for Health Information; 2000;
  3. Erdem Y, Haznedaroglu IC, Celik I, Yalcin AU, Yasavul U, Turgan C, et al. Coagulation, fibrinolysis and fibrinolysis inhibitors in haemodialysis patients: contribution of arteriovenous fistula. Nephrol Dial Transplant. 1996;11:1299–1305
  4. Hafner G, Klingel R, Wandel E, Ehrenthal W, Konheiser U, Lotz J, et al. Laboratory control of minimal heparinization during haemodialysis in patients with a risk of haemorrhage. Blood Coagul Fibrinolysis. 1994;5:221–226
  5. Lai KN, Yin JA, Yuen PM, Li PK. Protein C, protein S, and antithrombin III levels in patients on continuous ambulatory peritoneal dialysis and hemodialysis. Nephron. 1990;56:271–276
  6. Nakamura Y, Chida Y, Tomura S. Enhanced coagulation—fibrinolysis in patients on regular hemodialysis treatment. Nephron. 1991;58:201–204
  7. Tomura S, Nakamura Y, Tachibana K, Deguchi F, Ando R, Chida Y, et al. Enhanced coagulation and fibrinolysis during treatment with recombinant human erythropoietin in patients undergoing chronic hemodialysis. Blood Purif. 1993;11:370–377
  8. Warrell RPJ, Hultin MB, Coller BS. Increased factor VIII/von Willebrand factor antigen and von Willebrand factor activity in renal failure. Am J Med. 1979;66:226–228
  9. Tomura S, Nakamura Y, Deguchi F, Ando R, Chida Y, Marumo F. Coagulation and fibrinolysis in patients with chronic renal failure undergoing conservative treatment. Thromb Res. 1991;64:81–90
  10. Lottermoser K, Petras S, Poge U, Fimmers R, Hertfelder HJ, Schiermeyer B, et al. The fibrinolytic system in chronic renal failure. Eur J Med Res. 2001;6:372–376
  11. Sagedal S, Hartmann A, Sundstrom K, Bjornsen S, Brosstad F. Anticoagulation intensity sufficient for haemodialysis does not prevent activation of coagulation and platelets. Nephrol Dial Transplant. 2001;16:987–993
  12. Foley RN, Parfiey PS, Harnett JD, Kent GM, Martin CJ, Murray DC, et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int. 1995;47:186–192
  13. Prandoni P, Bilora F, Marchiori A, Bernardi E, Petrobelli F, Lensing AW, et al. An association between atherosclerosis and venous thrombosis. N Engl J Med. 2003;348:1435–1441
  14. Vazquez E, Sanchez-Perales C, Borrego F, Garcia-Cortes MJ, Lozano C, Guzman M, et al. Influence of atrial fibrillation on the morbido-mortality of patients on hemodialysis. Am Heart J. 2000;140:886–890
  15. Horattas MC, Wright DJ, Fenton AH, Evans DM, Oddi MA, Kamienski RW, et al. Changing concepts of deep venous thrombosis of the upper extremity—report of a series and review of the literature. Surgery. 1988;104:561–567
  16. Feldman HI, Held PJ, Hutchinson JT, Stoiber E, Hartigan MF, Berlin JA. Hemodialysis vascular access morbidity in the United States. Kidney Int. 1993;43:1091–1096
  17. Taylor JE, Henderson IS, Stewart WK, Belch JJ. Erythropoietin and spontaneous platelet aggregation in haemodialysis patients. Lancet. 1991;338:1361–1362
  18. Norton J, Spiezio R, LaManna L, DeLorme B. Varying heparin requirements in hemodialysis patients receiving erythropoietin. ANNA J. 1992;19:367–372
  19. Churchill DN, Muirhead N, Goldstein M, Posen G, Fay W, Beecroft ML, et al. Probability of thrombosis of vascular access among hemodialysis patients treated with recombinant human erythropoietin. J Am Soc Nephrol. 1994;4:1809–1813
  20. Tveit DP, Hypolite IO, Hshieh P, Cruess D, Agodoa LY, Welch PG, et al. Chronic dialysis patients have high risk for pulmonary embolism. Am J Kidney Dis. 2002;39:1011–1017
  21. Wiesholzer M, Kitzwogerer M, Harm F, Barbieri G, Hauser AC, Pribasnig A, et al. Prevalence of preterminal pulmonary thromboembolism among patients on maintenance hemodialysis treatment before and after introduction of recombinant erythropoietin. Am J Kidney Dis. 1999;33:702–708
  22. Wiesholzer M, Harm F, Tomasec G, Barbieri G, Putz D, Balcke P. Incidence of stroke among chronic hemodialysis patients with nonrheumatic atrial fibrillation. Am J Nephrol. 2001;21:35–39
  23. Iseki K, Kawazoe N, Osawa A, Fukiyama K. Survival analysis of dialysis patients in Okinawa, Japan (1971–1990). Kidney Int. 1993;43:404–409
  24. Churchill DN, Taylor DW, Cook RJ, LaPlante P, Barre P, Cartier P, et al. Canadian hemodialysis morbidity study. Am J Kidney Dis. 1992;19:214–234
  25. Chazan JA, London MR, Pono LM. Long-term survival of vascular accesses in a large chronic hemodialysis population. Nephron. 1995;69:228–233
  26. Droste DW, Kuhne K, Schaefer RM, Ringelstein EB. Detection of microemboli in the subclavian vein of patients undergoing haemodialysis and haemodiafiltration using pulsed Doppler ultrasound. Nephrology Dialysis Transplantation. 2002;17:462–466
  27. Smits HF, Van Rijk PP, Van Isselt JW, Mali WP, Koomans HA, Blankestijn PJ. Pulmonary embolism after thrombolysis of hemodialysis grafts. J Am Soc Nephrol. 1997;8:1458–1461
  28. Swan TL, Smyth SH, Ruffenach SJ, Berman SS, Pond GD. Pulmonary embolism following hemodialysis access thrombolysis/thrombectomy. J Vasc Interv Radiol. 1995;6:683–686
  29. Boaz M, Smetana S, Weinstein T, Matas Z, Gafter U, Iaina A, et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet. 2000;356:1213–1218
  30. Tepel M, van der GM, Statz M, Jankowski J, Zidek W. The antioxidant acetylcysteine reduces cardiovascular events in patients with-end-stage renal failure: a randomized, controlled trial. Cirulation. 2003;107:992–995
  31. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994;154:1449–1457
  32. Landefeld CS, Goldman L. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med. 1989;87:144–152
  33. Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med. 1998;105:91–99
  34. Wells PS, Forgie MA, Simms M, Greene A, Touchie D, Lewis G, et al. The outpatient bleeding risk index: validation of a tool for predicting bleeding rates in patients treated for deep venous thrombosis and pulmonary embolism. Arch Intern Med. 2003;163:917–920
  35. Crowther MA, Clase CM, Margetts PJ, Julian J, Lambert K, Sneath D, et al. Low-intensity warfarin is ineffective for the prevention of PTFE graft failure in patients on hemodialysis: a randomized controlled trial. J Am Soc Nephrol. 2002;13:2331–2337
  36. Kaufman JS, O'Connor TZ, Zhang JH, Cronin RE, Fiore LD, Ganz MB, et al. Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis. J Am Soc Nephrol. 2003;14:2313–2321
  37. Barritt DW, Jordan SC. Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial. Lancet. 1960;1:1309–1312
  38. Hull R, Dehnore T, Genton E, Hirsh J, Gent M, Sackett D, et al. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med. 1979;301:855–858
  39. Wilson SJ, Wells PS, Kovacs MJ, Lewis GM, Martin J, Burton E, et al. Comparing the quality of oral anticoagulant management by anticoagulation clinics and by family physicians: a randomized controlled trial. CMAJ. 2003;169:293–298
  40. Douketis JD, Kearon C, Bates S, Duku EK, Ginsberg JS. Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. JAMA. 1998;279:458–462
  41. Raschke RA, Reilly BM, Guidry JR, Fontana JR, Srinivas S. The weight-based heparin dosing nomogram compared with a “standard care” nomogram. A randomized controlled trial. Ann Intern Med. 1993;119:874–881
  42. Hyers TM, Agnelli G, Hull RD, Morris TA, Samama M, Tapson V, et al. Antithrombotic therapy for venous thromboembolic disease. Chest. 2001;119:176S–193S
  43. Hull RD, Raskob GE, Brant RF, Pineo GF, Elliott G, Stein PD, et al. Low-molecular-weight heparin vs. heparin in the treatment of patients with pulmonary embolism. American–Canadian Thrombosis Study Group. Arch Intern Med. 2000;160:229–236
  44. Simonneau G, Sors H, Charbonnier B, Page Y, Laaban JP, Azarian R, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard Evaluations dans 1’Embolie Puhnonaire. N Engl J Med. 1997;337:663–669
  45. Koopman MM, Prandoni P, Piovella F, Ockelford PA, Brandjes DP, van der MJ, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. [erratum appears in N Engl J Med 1997 Ott 23;337(17): 1251] N Engl J Med. 1996;334:682–687
  46. Kovacs MJ, Anderson D, Morrow B, Gray L, Touchie D, Wells PS. Outpatient treatment of pulmonary embolism with dalteparin. Thromb Haemost. 2000;83:209–211
  47. Bossuyt PM, van den Belt AG, Prins MH. Out-of-hospital treatment of venous thrombosis: socioeconomic aspects and patients' quality of life. Haemostasis. 1998;28(Suppl-7):
  48. Montenegro J, Martinez I, Saracho R, Gonzalez R. Beta 2 microglobulin in CAPD. Adv Perit Dial. 1992;8:369–372
  49. Laforest MD, Colas-Linhart N, Guiraud-Vitaux F, Bok B, Bara L, Samama M, et al. Pharmacokinetics and biodistribution of technetium 99m labelled standard heparin and a low molecular weight heparin (enoxaparin) after intravenous injection in normal volunteers. Br J Haematol. 1991;77:201–208
  50. Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R, et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest. 2001;119(Suppl-94S):
  51. Sanderink GJ, Guimart CG, Ozoux ML, Jariwala NU, Shukla UA, Boutouyrie BX. Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment. Thromb Res. 2002;105:225–231
  52. Schuhnan S. Unresolved issues in anticoagulant therapy. J Thromb Haemost. 2003;l:1464–1470
  53. Cadroy Y, Pourrat J, Baladre MF, Saivin S, Houin G, Montastruc JL, et al. Delayed elimination of enoxaparin in patients with chronic renal insufficiency. Thromb Res. 1991;63:385–390
  54. Gerlach AT, Pickworth KK, Seth SK, Tanna SB, Barnes JF. Enoxaparin and bleeding complications: a review in patients with and without renal insufficiency. Pharmacotherapy. 2000;20:771–775
  55. Collet JP, Montalescot G, Choussat R, Lison L, Ankri A. Enoxaparin in unstable angina patients with renal failure. Int J Cardiol. 2001;80:81–82
  56. Weitz JI. Low-molecular-weight heparins. N Engl J Med. 1997;337:688–698
  57. Fareed J, Jeske W, Hoppensteadt D, Clarizio R, Walenga JM. Are the available low-molecular-weight heparin preparations the same?. Semin Thromb Hemost. 1996;22(Suppl-91):
  58. Fareed J, Jeske W, Hoppensteadt D, Clarizio R, Walenga JM. Low-molecular-weight heparins: pharmacologic profile and product differentiation. Am J Cardiol. 1998;82:3L–10L
  59. Siguret V, Pautas E, Fevrier M, Wipff C, Durand-Gasselin B, Laurent M, et al. Elderly patients treated with tinzaparin (Innohep) administered once daily (175 anti-Xa IU/kg): anti-Xa and anti-IIa activities over 10 days. Thromb Haemost. 2000;84:800–804
  60. Pautas E, Gouin I, Bellot O, Andreux JP, Siguret V. Safety profile of tinzaparin administered once daily at a standard curative dose in two hundred very elderly patients. Drug Safety. 2002;25:725–733
  61. Hyers TM, Agnelli G, Hull RD, Morris TA, Samama M, Tapson V, et al. Antithrombotic therapy for venous thromboembolic disease. Chest. 2001;119(Suppl-193S):
  62. Greenfield LJ, Michna BA. Twelve-year clinical experience with the Greenfield vena caval filter. Surgery. 1988;104:706–712
  63. Decousus H, Leizorovicz A, Parent F, Page Y, Tardy B, Girard P, et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prevention du Risque d'Embolie Puhnonaire par Interruption Cave Study Group. N Engl J Med. 1998;338:409–415
  64. Kearon C, Gent M, Hirsh J, Weitz J, Kovacs MJ, Anderson DR, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med. 1999;340:901–907
  65. Becker DM, Philbrick JT, Selby JB. Inferior vena cava filters. Indications, safety, effectiveness. Arch Intern Med. 1662;152:1985–1994
  66. Koudstaal PJ. Anticoagulants for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attacks. The Cochrane Library (1). Chichester, UK: John Wiley and Sons, Ltd.; 2004;
  67. Segal JB, McNamara RL, Miller MR, Powe NR, Goodman SN, Robinson KA, et al. Anticoagulants or antiplatelet therapy for non-rheumatic atrial fibrillation and flutter. The Cochrane Library 1. Chichester, UK: John Wiley and Sons, Ltd.; 2004;
  68. Stroke Prevention Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: stroke prevention in atrial fibrillation III randomised clinical trial. Lancet. 1996;348:633–638
  69. Hylek EM, Go AS, Chang Y, Jensvold NG, Henault LE, Selby JV, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med. 2003;349:1019–1026
  70. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285:2864–2870
  71. Laupacis A, Boysen G, Connolly S, et al. The efficacy of aspirin in patients with atrial fibrillation: analysis of pooled data from 3 randomized trial. Arch Intern Med. 1997;157:1237–1240
  72. Ezekowitz M, Laupacis A, Boysen G, Connolly S, Hart R, James K, et al. Echocardiographic predictors of stroke in patients with atrial fibrillation—a prospective study of 1066 patients from 3 clinical trials. Arch Intern Med. 1998;158:1316–1320
  73. Anderson DC, Halperin JL, Hart RG, McAnulty JH, McBride R, Pearce LA, et al. Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin—stroke prevention in atrial fibrillation III study. JAMA. 1998;279:1273–1277
  74. Pearce LA, Hart RG, Halperin JL. Assessment of three schemes for stratifying stroke risk in patients with nonvalvular atrial fibrillation. Am J Med. 2000;75:45–51
  75. Hart RG, Pearce LA, McBride R, Rothbart RM, Asinger RW. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation—analysis of 2012 participants in the SPAF I–III clinical trials. Stroke. 1999;30:1223–1229
  76. Stroke Prevention in Atrial Fibrillation Investigators. Risk factors for thromboembolism during aspirin therapy in patients with atrial fibrillation: the stroke prevention in atrial fibrillation study. J Stroke Cerebrovasc Dis. 1995;5:147–157
  77. Devereaux PJ, Anderson DR, Gardner MJ, Putnam W, Flowerdew GJ, Brownell BF, et al. Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study. BMJ. 2001;323:1218–1222
  78. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med. 1999;131:492–501
  79. Mokrzycki MH, Jean-Jerome K, Rush H, Zdunek MP, Rosenberg SO. A randomized trial of minidose warfarin for the prevention of late malfunction in tunneled, cuffed hemodialysis catheters. Kidney Int. 2001;59:1935–1942
  80. NKF-K/DOQI . Clinical practice guidelines for vascular access: update 2000. Am J Kidney Dis. 2001;37(1 Suppl l):S137–S181
  81. Clase CM, Crowther MA, Ingram AJ, Cina CS. Thrombolysis for restoration of patency to dual-lumen haemodialysis catheters: a systematic review. J Thromb Thrombolysis. 2001;11:127–136

PII: S0049-3848(05)00214-8

doi: 10.1016/j.thromres.2005.03.031

Thrombosis Research
Volume 118, Issue 3 , Pages 385-395 , 2006

Article Tools